Drug Trial Radar · NCT07839936
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
175
Planned (sponsor's estimate)
Start
Sep 24, 2026
Primary completion
Aug 2028
Study completion Mar 2030
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Sep 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
Conditions
- Atherosclerosis
- Cardiovascular Disease
- Hypercholesterolemia
Interventions
VERVE-102Drug
Administered IV
PlaceboDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in LDL-CTime frame: Baseline, Day 90
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Epic Medical Research
DeSoto, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.